Arginase Activator

APL180 TFA (L-4F TFA) is an Apo-A1 mimetic peptide. APL180 TFA binds oxidized/oxidizable lipids with high affinity and sequesters pro-inflammatory oxidized lipids. APL180 TFA downregulates glycolysis-related genes and HIF-1α expression, and upregulates CD206 and Arginase. APL180 TFA inhibits atherosclerotic lesion progression and platelet aggregation. APL180 TFA attenuates adverse left ventricular remodeling and systolic dysfunction after myocardial infarction. APL180 TFA can be used for research on ovarian cancer.

Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis.

Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS). Perfluoroundecanoic acid is an orally active oxidative stress inducer. Perfluoroundecanoic acid promotes macrophage M2 polarization, activates Wnt/β-catenin signaling and enhances β-catenin nuclear accumulation. Perfluoroundecanoic acid -induced M2 phenotype macrophage accelerates tumor progression in vitro and in vivo. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Perfluoroundecanoic acid accelerates insulitis development in a mouse model of type 1 diabetes. Perfluoroundecanoic acid can be used for the study of ovarian cancer, type 1 diabetes and inflammation.

APL180 (L-4F) is an Apo-A1 mimetic peptide. APL180 binds oxidized/oxidizable lipids with high affinity and sequesters pro-inflammatory oxidized lipids. APL180 downregulates glycolysis-related genes and HIF-1α expression, and upregulates CD206 and Arginase. APL180 inhibits atherosclerotic lesion progression and platelet aggregation. APL180 attenuates adverse left ventricular remodeling and systolic dysfunction after myocardial infarction. APL180 can be used for research on ovarian cancer.

1-Hydroxy-4αH-1,10-secoeudesma-5(6),10(14),11(13)-trien-12,8β-olide is a neuroprotective agent. 1-Hydroxy-4αH-1,10-secoeudesma-5(6),10(14),11(13)-trien-12,8β-olide reduces the protein expression levels of iNOS and COX-2, blocks the DNA-binding activity of NF-κB, and inhibits nitric oxide production. 1-Hydroxy-4αH-1,10-secoeudesma-5(6),10(14),11(13)-trien-12,8β-olide promotes the polarization of microglia to the M2 phenotype by inducing the production of Arg-1, and alleviates cell damage induced by H₂O₂ and 6-Hydroxydopamine (HY-B1081).

Lacto-N-fucopentaose III (LNFP-III) is an immune modulator. Lacto-N-fucopentaose III reduces the severity of experimental autoimmune encephalomyelitis (EAE) and CNS inflammation.